

11 May 2016

ASX Code: MXC

European Commission Approves MGC Derma Cosmetics Products

- MGC Pharmaceuticals has received approval from the European Commission's Cosmetic Products Notification Portal (CPNP), for its MGC Derma Cannabidiol (CBD) based cosmetic products
- CPNP is the European Union (EU) body responsible for regulating the European cosmetics market
- Allows retail consumers throughout the EU to freely purchase the MGC Derma cosmetics online and sets the platform for MGC Pharma to undertake new distribution agreements in EU countries
- Similar approval applications already underway with the US Food and Drug Administration (FDA) and the Australian Therapeutics Goods Association (TGA)
- Significant commercial milestone achieved, allowing the Company to commence dedicated marketing and sales efforts for its cosmetics products throughout EU countries

MGC Pharmaceuticals Ltd (ASX:MXC or "the Company") is pleased to announce that it has been granted approval from the European Commission's Cosmetic Products Notification Portal (CPNP), for its MGC Derma CBD based cosmetic products, enabling the Company to freely market, sell and distribute freely its products throughout the European Union (EU).

The European Commission's CPNP is the registration portal that facilitates approvals for cosmetic products to be marketed in the EU. The marketing approval covers the distribution of the Company's 16 initial CBD-based cosmetics products in its MGC Derma Ananda product line, which includes a Moisturising Day Cream SPF 50, Active Firming Anti-Aging Mask, Active Whitening Facial Cream, Anti Puffiness and Dark Circles Eye Serum.

Following the recent launch of MGC Derma's online retail shop at www.mgcderma.com, retail consumers throughout the EU, and other countries where CBD cosmetics are legal, are able to purchase the cosmetics from the Company's online platform. Similarly, the Company's first European distribution partner, Czech Medical Herbs, s.r.o. (CMH) can now commence distribution and sales of the product line to its network, and the Company can advance discussions with other potential European distribution partners.

Importantly, with the CPNP approval successfully received, MGC Pharmaceuticals confirms it has also lodged formal applications seeking similar approvals from both the US FDA and the Australian TGA, the regulatory bodies responsible for approving therapeutics in the US and Australian respectively, for the cosmetics line. The outcomes of these applications are expected in the coming months and if positive, would further facilitate the Company's proposed expansion into the large global cosmetics market, currently estimated to be worth \$US460 billion in 2014.

Nativ Segev, Co-founder and Managing Director, MGC Pharmaceuticals Limited commented:

“Receiving approval from the European Commission’s Cosmetic Products Notification Portal marks a significant milestone for MGC Pharmaceuticals. It allows the Company to commence dedicated marketing and sales efforts for its cosmetics products throughout the EU and furthering our move towards material revenue generation, as part of the large global cosmetics market.”

-Ends-

For further information, please contact:

Media Enquiries

Andrew Ramadge
Senior Account Manager
Media and Capital Partners
+61 475 797 471
andrew.ramadge@mcpartners.com.au

MGC Pharmaceuticals Ltd

Brett Mitchell
Executive Chairman
+61 8 9389 2000
info@mgcpharma.com.au

About MXC

MGC Pharmaceuticals Ltd (ASX: MXC) is EU based specialist medical cannabis company with many years of technical and commercial experience in the medical cannabis industry. The Company’s founders were key figures in the Israeli medical cannabis industry and the core business strategy is to develop and supply high quality non-psychoactive Cannabidiol (CBD) resin extract to the growing European cosmetics and medical markets.